J&J inks industry's latest bolt-on buyout with $6.5B deal to acquire Momenta, beefing up its autoimmune pipeline
Early Wednesday J&J put out word that it is paying $52.50 a share to bag the company. The deal nets out at $6.1 billion once you factor in cash on hand at the biotech.
The prize for J&J is nipocalimab (M281), which the company describes as a “clinically validated, potentially best-in-class anti-FcRn antibody” with potential in a range of diseases like maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. That qualifies as a pipeline in a product, a key theme these days in M&A.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.